FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010641595> ?p ?o ?g. }

• W2010641595 endingPage "1794" @default.
• W2010641595 startingPage "1790" @default.
• W2010641595 abstract "HomeCirculationVol. 108, No. 15Aldosterone Blockade in Patients With Systolic Left Ventricular Dysfunction Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBAldosterone Blockade in Patients With Systolic Left Ventricular Dysfunction Bertram Pitt Bertram PittBertram Pitt From the University of Michigan School of Medicine, Ann Arbor, Mich. Search for more papers by this author Originally published14 Oct 2003https://doi.org/10.1161/01.CIR.0000086776.15268.22Circulation. 2003;108:1790–1794The patient, W.L., is a 62-year-old white man with a history of hypertension, hypercholesterolemia, and an anterior Q-wave myocardial infarction 3 years ago. He has had 2 admissions for heart failure in the past 6 months. He was last discharged 2 months ago on aspirin 325 mg daily, simvastatin 40 mg daily, enalapril 10 mg BID, metoprolol XL 100 mg daily, digoxin 0.25 mg daily, and furosemide 120 mg BID. Over the past month, he has noted some increasing dyspnea on exertion and occasional episodes of paroxysmal nocturnal dyspnea but has not had any increase in peripheral edema or body weight. His left ventricular ejection fraction on discharge from the hospital 2 months ago was 26%, with evidence of a large anterior akinetic area but without evidence of inducible myocardial ischemia on dobutamine echocardiography. His laboratory data today included a hematocrit of 41%, serum creatinine 1.1 mg%, potassium 4.1 meq/L, fasting blood sugar 108 mg%, LDL cholesterol 92 mg/dL, HDL cholesterol 45 mg/dL, triglycerides 188 mg/dL, serum digoxin level 1.2, and brain natriuretic peptide (BNP) (Biosite) 508. ECG revealed evidence of an old anterior myocardial infarction, and chest x-ray showed cardiomegaly with some increase in pulmonary vascularity. At this time, would you suggest any change in his medical regimen?Angiotensin-converting enzyme (ACE) inhibition and β-blockade have been shown effective in improving survival in patients with systolic left ventricular dysfunction (SLVD) resulting from both ischemic and nonischemic cardiomyopathy; they are indicated in all patients with heart failure (HF) caused by SLVD unless contraindicated or not tolerated. Although they improve the symptoms of HF, loop diuretics and digoxin have not been shown to reduce mortality rate. There is, however, increasing evidence that aldosterone blockade is effective in reducing mortality and morbidity rates in patients with HF caused by SLVD that is associated with both ischemic and nonischemic etiologies.1,2 Aldosterone-blocking agents have also been shown to be effective in controlling blood pressure in patients with essential hypertension and reducing left ventricular mass, myocardial fibrosis, microalbuminuria, and vascular compliance.3,4 Their effects on morbidity and/or mortality in patients with essential hypertension, and whether they provide a reduction in clinical events independent of blood pressure-lowering effects, are as yet unknown. Before we further discuss patient W.L., the evidence relating to the role of aldosterone blockade in patients with SLVD will be briefly reviewed.Effect of Aldosterone Blockade in Patients With Chronic HF Caused by SLVDThe Randomized Aldactone Evaluation Study (RALES)1 evaluated the role of the aldosterone blocker spironolactone in patients with New York Heart Association class III to IV HF, a history of NYHA class IV HF resulting from either ischemic or nonischemic etiology during the previous 6 months, and a left ventricular ejection fraction ≤40%. Patients with renal dysfunction (creatinine >2.5 mL/dL) and those with serum potassium >5.0 meq/L were excluded. In this study of >1600 patients followed up for a mean of 2 years, spironolactone at a mean dose of 26 mg daily given on top of standard therapy, which included an ACE inhibitor and diuretic with or without digoxin and a β-blocker, was associated with a 30% reduction in all-cause mortality (P<0.001) and a 35% reduction (P<0.001) in hospitalization for HF. The reduction in all-cause mortality was the result of both a 36% reduction (P<0.001) in death from progressive HF and a 29% reduction (P=0.02) in sudden cardiac death. The major adverse effect of spironolactone was an increase in gynecomastia and breast pain in males. There was also an absolute increase of 1% in serious hyperkalemia (K+ ≥6.0 meq/L) in patients randomized to spironolactone compared with placebo (P=NS). The beneficial effects of spironolactone on mortality rate were relatively uniform across a number of predefined subgroups.On the basis of this study, spironolactone has been recommended for the treatment of severe HF caused by SLVD in both the United States and European guidelines. The adoption of these recommendations into clinical practice has, however, been variable because the recommendation was based on a single trial, and only 10% to 11% of patients in that study were on a β-blocker.1 Further information on the role of aldosterone blockade in patients with HF caused by SLVD has become available from the Eplerenone Post-acute myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS).2Effect of Aldosterone Blockade in Patients With SLVD After Acute Myocardial InfarctionEPHESUS2 randomized >6600 patients with evidence of an acute myocardial infarction (AMI), a left ventricular ejection fraction ≤40%, and evidence of HF (except patients with diabetes mellitus, who were required to have only evidence of SLVD) to the selective aldosterone blocker eplerenone or placebo 3 to 14 days after infarction. Patients with a serum creatinine ≥2.5 mg/dL and those with evidence of serum potassium ≥5.0 meq/L were excluded. Study medication was administered a mean of 7.3 days after infarction, beginning at a dose of 25 mg daily for 1 month and then uptitrated to 50 mg daily unless there was evidence of hyperkalemia. Patients randomized to eplerenone at a mean dose of 43 mg daily over a mean follow-up of 16 months had a 15% reduction in total mortality (P=0.008) (co-primary end point), a 17% reduction in cardiovascular mortality (P=0.005), and a 13% reduction in cardiovascular mortality/cardiovascular hospitalizations (P=0.002), including hospitalization for myocardial infarction, stroke, HF, and ventricular arrhythmias (co-primary end point). The major cause of cardiovascular death in this study was sudden cardiac death, which was reduced by 21% (P=0.003) in patients randomized to eplerenone. The major cause of cardiovascular hospitalizations was HF. Fifteen percent fewer patients (P=0.03) were hospitalized for HF in patients randomized to eplerenone and had 23% fewer episodes of hospitalization for HF (P=0.002). Of particular interest was the finding that eplerenone was effective in reducing all-cause mortality as well as cardiovascular mortality/cardiovascular hospitalization in patients on an ACE inhibitor or an angiotensin receptor-blocking agent (ARB) and a β-blocker. Furthermore, eplerenone had a beneficial effect in patients on optimal therapy post-infarction, which included an aspirin, statin, reperfusion within 14 days of myocardial infarction, an ACE inhibitor or ARB, and a β-blocker.In contrast to the experience in RALES,1 there was no excess of gynecomastia, breast pain, or impotence in males, attesting to the selectivity of eplerenone for the mineralocorticoid receptor in comparison to spironolactone, which also binds to androgen and progesterone receptors. There was a 1.6% absolute increase in serious hyperkalemia (K+ ≥6.0 meq/L) in patients randomized to eplerenone (P=0.002). There was, however, a 4.7% absolute decrease in the incidence of hypokalemia (K+ ≤3.5 meq/L) in patients randomized to eplerenone compared with placebo (P≤0.001). Although results of the EPHESUS trial have been reported,2 it should be emphasized that these results are under review by the US Food and Drug Administration, and eplerenone is not yet indicated for the treatment of SLVD after AMI.Effect of Aldosterone Blockade on Potassium HomeostasisSince the publication of RALES,1 there have been several reports of hyperkalemia associated with the use of spironolactone in patients with HF caused by SLVD.5–10 Many of these reported episodes of hyperkalemia were associated with hospitalization, renal dysfunction, need for renal dialysis, and in some instances death. Such reports have caused concern, and many clinicians are reluctant to attempt aldosterone blockade. A review of these reports, however, suggests that the majority of episodes of serious hyperkalemia (K+ ≥6.0 meq/L) associated with aldosterone blockade were at doses above those recommended in RALES1 and occurred in patients excluded from RALES. Furthermore, serum potassium was often not monitored as recommended in RALES, and the dose of aldosterone blockade was not adjusted according to the level of serum potassium.In RALES,1 spironolactone was administered at a dose of 25 mg daily. It was recommended that serum potassium monitoring occur 1 week after initiating therapy, at 1 month, and thereafter every 3 months. An increase in serum potassium ≥5.5 meq/L at any time prompted a review of concomitant medications associated with hyperkalemia, such as potassium supplements or nonsteroidal antiinflammatory agents, and a reduction of the dose of study medication to 25 mg every other day. If, after 4 weeks of therapy, there was no evidence of a serum potassium ≥5.5 meq/L but symptomatic evidence of progressive HF, the dose of study medication could be increased to 50 mg daily. The mean dose of spironolactone in RALES was 26 mg daily; approximately 70% of patients were on 25 mg daily, 15% on 25 mg every other day, and 15% on 50 mg daily. The finding of a serum potassium ≥6.0 meq/L at any time prompted the temporary discontinuation of study medication, which could be reinstituted after adjusting concomitant medication and the return of serum potassium to <5.5 meq/L. In EPHESUS,2 eplerenone was initiated at 25 mg daily for 1 month and then increased to 50 mg daily (a dose approximately equivalent to 25 mg a day of spironolactone) with a similar recommendation for monitoring of serum potassium and adjustment of study medication according to serum potassium measurements. This strategy, both in RALES1 and EPHESUS,2 was not associated with the adverse events noted in clinical practice with spironolactone. It should, however, be pointed out that there have been occasional episodes of serious hyperkalemia associated with the use of spironolactone even when the RALES recommendations are followed.1 This may relate in part to the recommendation to exclude patients with a serum creatinine >2.5 mg/dL. Such a strategy appears inadequate in elderly patients, those with a low body mass index, and those with diabetes mellitus because serum creatinine may underestimate renal dysfunction in these circumstances. On the basis of experience in RALES1 and EPHESUS,2 it would be prudent to exclude patients with severe renal dysfunction and a creatinine clearance ≤30 mL/min and to be cautious in those with a creatinine clearance between 30 and 50 mL/min, who should be followed up even more closely than recommended in the RALES recommendations for monitoring of serum potassium and creatinine.It is important to emphasize that although aldosterone blockade is effective in reducing mortality on top of an ACE inhibitor or ARB and a β-blocker, it is essential to monitor serum potassium. Potassium blood levels may be monitored at any convenient laboratory and do not require a patient visit to the physician. Failure to follow the dosing recommendations in RALES1 and EPHESUS2 and to recognize the potential for serious hyperkalemia could result in renal dysfunction and possibly death. If, however, the physician is willing to monitor serum potassium, adjust the dose of aldosterone blocker according to the level of serum potassium, exclude those with severe renal insufficiency, and cautiously monitor those with mild-to-moderate renal insufficiency, it is apparent from the RALES1 and EPHESUS2 studies that patients with SLVD will benefit from an improvement in mortality as well as morbidity.Although aldosterone blockade is associated with an increase in serious hyperkalemia, it also can protect against hypokalemia (K+ ≤3.5 meq/L). Hypokalemia may be as great or potentially a greater risk than hyperkalemia in patients with HF. In patients with systolic hypertension in the Systolic Hypertension in the Elderly Program (SHEP) trial,11 blood pressure was controlled with a diuretic with or without a β-blocker and resulted in a significant reduction in cardiovascular events. However, ≈7% of patients in SHEP developed hypokalemia. In these patients, the benefit of blood pressure control on cardiovascular events was negated. In patients with HF caused by SLVD, Cooper et al12 have found that patients treated with a loop diuretic in the Studies Of Left Ventricular Dysfunction trial had an increase in mortality compared with those not on a diuretic. Although this could reflect the fact that patients on a diuretic had more severe HF than those not on a diuretic, it is important to note that those patients on a potassium-sparing diuretic, mainly spironolactone, had a reduction in mortality both from progressive HF and sudden cardiac death in comparison to those on a diuretic. In EPHESUS,2 there were almost twice as many episodes of hypokalemia prevented than episodes of hyperkalemia induced by eplerenone.How Long Should an Aldosterone Blocker Be Administered?In patients with severe chronic HF caused by SLVD, an aldosterone blocker should be maintained indefinitely, as should an ACE inhibitor and a β-blocker. In patients with SLVD and HF after AMI, the optimum duration of treatment is less certain. One approach might be to maintain an aldosterone blocker indefinitely in those patients with persistent left ventricular systolic dysfunction (left ventricular ejection fraction ≤40%) or signs of HF. In those patients who improve their left ventricular ejection fraction ≥40% and in those who are asymptomatic, it might be reasonable to consider withholding the aldosterone blocker after a period of 1 to 2 years. A final recommendation must await a more detailed analysis of the EPHESUS trial2 (in which the mean follow-up was 16 months; range, 0 to 33 months).Which Aldosterone Blocker?In patients with severe HF caused by SLVD, it would be reasonable to consider spironolactone according to the dosing regimen recommended in RALES.1 Those male patients who develop gynecomastia, breast pain, or impotence and those females who develop menstrual irregularities or other spironolactone-related side effects should be given a trial of eplerenone 25 to 50 mg daily, when available, to maintain aldosterone blockade.In post-AMI patients, evidence-based medicine would suggest administering eplerenone according to the dosing regimen in EPHESUS.2 When cost is a major factor and relatively short-term use of aldosterone blockade is anticipated, one might consider administering spironolactone according to the dosing regimen in RALES.1 One should, however, be cautious in applying 25 mg of spironolactone to patients with an AMI without further evidence from a larger number of patients. Initial experience by Hayashi et al13 using intravenous canrenoate, a metabolite of spironolactone, on day 1 post-infarction after percutaneous reperfusion followed by 25 mg of spironolactone daily for 1 month suggests that this regimen is effective in preventing ventricular remodeling and collagen formation. The effects of this dosing regimen on morbidity and mortality are uncertain. Although both spironolactone and eplerenone block the effect of aldosterone at the mineralocorticoid receptor, there are insufficient data at this time to be confident about their relative effectiveness and risk/benefit ratio. For example, because of its metabolite potassium canrenoate, spironolactone has a relatively longer half-life than eplerenone. It can be postulated that the longer half-life of spironolactone could result in a higher incidence of hyperkalemia in comparison to eplerenone. Similarly, the effects of spironolactone on androgen and prostagen receptors might have beneficial or detrimental effects on the cardiovascular system other than those seen in EPHESUS.2 Clearly, further prospective direct trials comparing spironolactone to eplerenone will be necessary to determine if there are any differences in their risk/benefit ratio. In the interim, it would be prudent to use the drug regimen and indications proven by the pivotal prospective randomized studies.1,2Which Patients Should Be Treated With an Aldosterone Blocker?Aldosterone blockade is effective in patients with severe chronic HF caused by SLVD associated with both ischemic and nonischemic cardiomyopathy.1 It has also been found effective in patients with HF caused by SLVD after AMI. Although evidence suggests that ventricular remodeling, endothelial function, heart rate variability, baroreceptor function, and myocardial collagen formation are improved by aldosterone blockade in patients with mild-to-moderate HF caused by SLVD (NYHA class II through III),14,15,16 there is no prospective evidence from randomized studies as to the effect of aldosterone blockade on mortality or morbidity in these patients. It might, however, be reasonable to extrapolate from the results of aldosterone blockade in those patients with severe chronic HF studied in RALES,1 and those with less severe HF studied in EPHESUS after infarction, to those with mild-to-moderate chronic HF. Until further data are available, it would not be reasonable to extrapolate the findings in RALES1 and EPHESUS2 to those patients with HF caused by preserved systolic function and those with asymptomatic SLVD without further prospective randomized studies powered to evaluate clinical events.Mechanism of Action of Aldosterone BlockadeAldosterone-blocking agents are known to increase diuresis and natriuresis and to lower blood pressure in patients with essential hypertension while sparing potassium. Although these “classic” effects of aldosterone blockade may account for its effects in controlling blood pressure, over the past several years, other nonrenal effects of aldosterone blockade have been demonstrated that may in large part be responsible for its beneficial effects in patients with SLVD after AMI and in chronic HF. These mechanisms have been recently reviewed17–27 and include: an effect on vascular inflammation, vascular remodeling and compliance, ventricular hypertrophy and fibrosis, endothelial dysfunction, myocardial norepinephrine uptake, heart rate variability, baroreceptor function, fibrinolysis, and platelet activation.Future Indications for Aldosterone BlockadeOther potential indications for aldosterone blockade will require further prospective evaluation, including patients with HF with preserved systolic function; those with asymptomatic SLVD; prevention of mortality and morbidity in patients with essential hypertension and left ventricular hypertrophy; prevention of progressive renal dysfunction; prevention of the progression of atherosclerosis, and prevention of ischemic events. Our understanding of the role of aldosterone blockade in patients with cardiovascular disease is still in its early stage. The mechanisms associated with the beneficial effects of aldosterone blockade on mortality and morbidity in patients with SLVD are still incompletely understood. Although predicting the outcome of future randomized studies is difficult, it is reasonable to postulate that the beneficial effects of aldosterone blockade in the RALES1 and EPHESUS2 studies in patients with SLVD treated with standard therapy including an ACE inhibitor and a β-blocker likely will extend beyond these indications.Patient W.L.On the basis of the above discussion, it would appear reasonable to recommend that patient W.L., with evidence of an ischemic cardiomyopathy and recent hospitalizations for HF despite “optimal therapy,” be given an aldosterone-blocking agent.Dr Pitt has served as a consultant to Pfizer.FootnotesCorrespondence to Bertram Pitt, MD, University of Michigan School of Medicine, 3901 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0366. References 1 Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709–717.CrossrefMedlineGoogle Scholar2 Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309–1321.CrossrefMedlineGoogle Scholar3 Weber M. Clinical implications of aldosterone blockade. Am Heart J. 2002; 144 (suppl 5): S12–S18.CrossrefMedlineGoogle Scholar4 Pitt B, Reichek N, Metscher B, et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy. Circulation. In press.Google Scholar5 Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003; 41: 211–214.CrossrefMedlineGoogle Scholar6 Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart. 2001; 85: E8.CrossrefMedlineGoogle Scholar7 Georges B, Beguin C, Jadoul M. Spironolactone and congestive heart failure. Lancet. 2000; 355: 1369–1370.Google Scholar8 McMullan R, Silke B. Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic. Ulster Med J. 2001; 70: 111–115.MedlineGoogle Scholar9 Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001; 110: 438–441.CrossrefMedlineGoogle Scholar10 Tamirisa K, Aaronson K, Cody R, et al. Spironolactone-induced renal impairment and hyperkalemia in patients with heart failure: can we predict these side effects? J Am Coll Cardiol. 2003; 41 (suppl 6): 162A.Google Scholar11 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991; 265: 3255–3264.CrossrefMedlineGoogle Scholar12 Cooper H, Dries D, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999; 100: 1311–1315.CrossrefMedlineGoogle Scholar13 Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003; 107: 2559–2565.LinkGoogle Scholar14 Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000; 101: 1722–1728.CrossrefMedlineGoogle Scholar15 Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2002; 37: 1800–1807.Google Scholar16 Modena MG, Aveta P, Menozzi A, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 2001; 141: 41–46.CrossrefMedlineGoogle Scholar17 Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001; 12: 308–314.CrossrefMedlineGoogle Scholar18 Rajagopalan S, Pitt B. Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep. 2001; 3: 240–248.CrossrefMedlineGoogle Scholar19 Funder J. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J. 2002; 144: S8–S11.CrossrefMedlineGoogle Scholar20 Liew D, Krum H. The role of aldosterone receptor blockade in the management of cardiovascular disease. Curr Opin Investig Drugs. 2002; 3: 1468–1473.MedlineGoogle Scholar21 Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000; 85: 336–344.MedlineGoogle Scholar22 Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000; 57: 1408–1411.CrossrefMedlineGoogle Scholar23 Rocha R, Williams G. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs. 2002; 62: 723–731.CrossrefMedlineGoogle Scholar24 Rajagopalan S, Pitt B. Aldosterone as a target in congestive heart failure. Med Clin North Am. 2003; 87: 441–457.CrossrefMedlineGoogle Scholar25 Virdis A, Neves M, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002; 40: 504–510.LinkGoogle Scholar26 Zhang Z, Francis J, Weiss R, et al. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol. 2002; 283: H423–H433.CrossrefMedlineGoogle Scholar27 Weber K. Aldosterone in congestive heart failure. N Engl J Med. 2001; 345: 1689–1697.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Shao C, Wang J, Tian J and Tang Y (2020) Coronary Artery Disease: From Mechanism to Clinical Practice Coronary Artery Disease: Therapeutics and Drug Discovery, 10.1007/978-981-15-2517-9_1, (1-36), . Feingold B, Mahle W, Auerbach S, Clemens P, Domenighetti A, Jefferies J, Judge D, Lal A, Markham L, Parks W, Tsuda T, Wang P and Yoo S (2017) Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association, Circulation, 136:13, (e200-e231), Online publication date: 26-Sep-2017. Bangalore S, Kumar S and Messerli F (2012) When Conventional Heart Failure Therapy is Not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist?, Congestive Heart Failure, 10.1111/chf.12011, 19:3, (107-115), Online publication date: 1-May-2013. OPIE L and PFEFFER M (2013) Inhibitors of the renin-angiotensin-aldosterone system Drugs for the Heart, 10.1016/B978-1-4557-3322-4.00014-4, (119-168), . OPIE L, VICTOR R and KAPLAN N (2013) Diuretics Drugs for the Heart, 10.1016/B978-1-4557-3322-4.00013-2, (93-118), . Freudenberger R and Kostis J (2013) Heart Failure in Hypertension Hypertension: A Companion to Braunwald’s Heart Disease, 10.1016/B978-1-4377-2766-1.00029-6, (262-269), . Kolkhof P and Borden S (2012) Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics, Molecular and Cellular Endocrinology, 10.1016/j.mce.2011.06.025, 350:2, (310-317), Online publication date: 1-Mar-2012. Kantor P and Mertens L (2010) Clinical practice, European Journal of Pediatrics, 10.1007/s00431-009-1133-7, 169:4, (403-410), Online publication date: 1-Apr-2010. Pitt B (2009) Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?, Current Heart Failure Reports, 10.1007/s11897-009-0017-5, 6:2, (112-116), Online publication date: 1-Jun-2009. Wei Y, Whaley-Connell A, Habibi J, Rehmer J, Rehmer N, Patel K, Hayden M, DeMarco V, Ferrario C, Ibdah J and Sowers J (2008) Mineralocorticoid Receptor Antagonism Attenuates Vascular Apoptosis and Injury via Rescuing Protein Kinase B Activation, Hypertension, 53:2, (158-165), Online publication date: 1-Feb-2009. van den Borne S, Isobe S, Zandbergen H, Li P, Petrov A, Wong N, Fujimoto S, Fujimoto A, Lovhaug D, Smits J, Daemen M, Blankesteijn W, Reutelingsperger C, Zannad F, Narula N, Vannan M, Pitt B, Hofstra L and Narula J (2009) Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling, JACC: Cardiovascular Imaging, 10.1016/j.jcmg.2008.11.011, 2:2, (187-198), Online publication date: 1-Feb-2009. OPIE L and PFEFFER M (2009) Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin Drugs for the Heart, 10.1016/B978-1-4160-6158-8.50010-1, (112-159), . OPIE L and KAPLAN N (2009) Diuretics Drugs for the Heart, 10.1016/B978-1-4160-6158-8.50009-5, (88-111), . Lopes R, Lourenço A, Mascarenhas J, Azevedo A and Bettencourt P (2008) Safety of Spironolactone Use in Ambulatory Heart Failure Patients, Clinical Cardiology, 10.1002/clc.20284, 31:11, (509-513), Online publication date: 1-Nov-2008. Struthers A, Krum H and Williams G (2008) A Comparison of the Aldosterone-blocking Agents Eplerenone and Spironolactone, Clinical Cardiology, 10.1002/clc.20324, 31:4, (153-158), Online publication date: 1-Apr-2008. Baker T, Nikolic´ G and O'Connor S (2008) THE PATIENT WITH CHEST PAIN Practical Cardiology, 10.1016/B978-0-7295-3841-1.10004-8, (117-187), . Grossmann C and Gekle M (2007) Non-classical actions of the mineralocorticoid receptor: Misuse of EGF receptors?, Molecular and Cellular Endocrinology, 10.1016/j.mce.2007.07.001, 277:1-2, (6-12), Online publication date: 1-Oct-2007. Davies S (2007) Aldosterone antagonists in heart failure, British Journal of Cardiac Nursing, 10.12968/bjca.2007.2.7.23810, 2:7, (342-350), Online publication date: 1-Jul-2007. Zeller T, Rastan A, Schwarzwälder U, Müller C, Frank U, Bürgelin K, Sixt S, Schwarz T, Noory E and Neumann F (2007) Regression of Left Ventricular Hypertrophy Following Stenting of Renal Artery Stenosis, Journal of Endovascular Therapy, 10.1583/1545-1550(2007)14[189:ROLVHF]2.0.CO;2, 14:2, (189-197), Online publication date: 1-Apr-2007. Zeller T, Rastan A, Schwarzwälder U, Müller C, Frank U, Bürgelin K, Sixt S, Schwarz T, Noory E and Neumann F (2016) Regression of Left Ventricular Hypertrophy following Stenting of Renal Artery Stenosis, Journal of Endovascular Therapy, 10.1177/152660280701400211, 14:2, (189-197), Online publication date: 1-Apr-2007. Pitt B (2007) Drug safety: who is responsible?, International Journal of Clinical Practice, 10.1111/j.1742-1241.2006.01257.x, 61:2, (182-184) Tse H (2007) Hypertension in Patients with Concomitant Cardiac Disorders Comprehensive Hypertension, 10.1016/B978-0-323-03961-1.50065-9, (753-759), . Pitt B, Ferrari R, Gheorghiade M, van Veldhuisen D, Krum H, McMurray J and Lopez-Sendon J (2007) Aldosterone blockade in post-acute myocardial infarction heart failure, Clinical Cardiology, 10.1002/clc.4960291004, 29:10, (434-438), Online publication date: 1-Oct-2006. Baliga R, Ranganna P, Pitt B and Koelling T (2006) Spironolactone Treatment and Clinical Outcomes in Patients With Systolic Dysfunction and Mild Heart Failure Symptoms: A Retrospective Analysis, Journal of Cardiac Failure, 10.1016/j.cardfail.2006.01.013, 12:4, (250-256), Online publication date: 1-May-2006. Ko D, Juurlink D, Mamdani M, You J, Wang J, Donovan L and Tu J (2006) Appropriateness of Spironolactone Prescribing in Heart Failure Patients: A Population-Based Study, Journal of Cardiac Failure, 10.1016/j.cardfail.2006.01.003, 12:3, (205-210), Online publication date: 1-Apr-2006. Goodfriend T (2007) Aldosterone—A Hormone of Cardiovascular Adaptation and Maladaptation, The Journal of Clinical Hypertension, 10.1111/j.1524-6175.2006.05110.x, 8:2, (133-139), Online publication date: 1-Feb-2006. ADAMS K and PATIERSON H (2005) Pharmacological therapy The Year in Heart Failure, 10.1201/9780203500484-5, (67-88) Coca S, Perazella M and Buller G (2005) The cardiovascular implications of hypokalemia, American Journal of Kidney Diseases, 10.1053/j.ajkd.2004.10.015, 45:2, (233-247), Online publication date: 1-Feb-2005. Barnes B and Howard P (2005) Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure, Annals of Pharmacotherapy, 10.1345/aph.1E306, 39:1, (68-76), Online publication date: 1-Jan-2005. Howard P (2017) The Role of Aldosterone Antagonists in Systolic Heart Failure, Hospital Pharmacy, 10.1177/001857870403901004, 39:10, (944-953), Online publication date: 1-Oct-2004. Xiao F, Puddefoot J, Barker S and Vinson G (2004) Mechanism for Aldosterone Potentiation of Angiotensin II–Stimulated Rat Arterial Smooth Muscle Cell Proliferation, Hypertension, 44:3, (340-345), Online publication date: 1-Sep-2004.Perrier E, Kerfant B, Lalevee N, Bideaux P, Rossier M, Richard S, Gómez A and Benitah J (2004) Mineralocorticoid Receptor Antagonism Prevents the Electrical Remodeling That Precedes Cellular Hypertrophy After Myocardial Infarction, Circulation, 110:7, (776-783), Online publication date: 17-Aug-2004. Deswal A and Yao D (2004) Aldosterone receptor blockers in the treatment of heart failure, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-004-0034-3, 6:4, (327-334), Online publication date: 1-Aug-2004. Konstam M, Lindenfeld J, Pina I, Packer M, Lazar R and Warner Stevenson L (2004) Key issues in trial design for ventricular assist devices: a position statement of the heart failure society of America, Journal of Cardiac Failure, 10.1016/j.cardfail.2004.02.009, 10:2, (91-100), Online publication date: 1-Apr-2004. Carey R and Logan A (2004) Clinical trials report, Current Hypertension Reports, 10.1007/s11906-004-0085-6, 6:2, (113-116), Online publication date: 1-Apr-2004. Keating G and Plosker G (2004) Eplerenone, Drugs, 10.2165/00003495-200464230-00005, 64:23, (2689-2707), . October 14, 2003Vol 108, Issue 15 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000086776.15268.22PMID: 14557343 Originally publishedOctober 14, 2003 PDF download Advertisement" @default.
• W2010641595 created "2016-06-24" @default.
• W2010641595 creator A5042843111 @default.
• W2010641595 date "2003-10-14" @default.
• W2010641595 modified "2023-09-23" @default.
• W2010641595 title "Aldosterone Blockade in Patients With Systolic Left Ventricular Dysfunction" @default.
• W2010641595 cites W1970945202 @default.
• W2010641595 cites W2005806825 @default.
• W2010641595 cites W2005862934 @default.
• W2010641595 cites W2007204386 @default.
• W2010641595 cites W2019397935 @default.
• W2010641595 cites W2027163029 @default.
• W2010641595 cites W2037682838 @default.
• W2010641595 cites W2047458689 @default.
• W2010641595 cites W2076117260 @default.
• W2010641595 cites W2112806972 @default.
• W2010641595 cites W2128246009 @default.
• W2010641595 cites W2139764595 @default.
• W2010641595 cites W2151974006 @default.
• W2010641595 cites W2152094259 @default.
• W2010641595 cites W2160982549 @default.
• W2010641595 cites W2168453807 @default.
• W2010641595 cites W2323458614 @default.
• W2010641595 cites W4249101651 @default.
• W2010641595 doi "https://doi.org/10.1161/01.cir.0000086776.15268.22" @default.
• W2010641595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14557343" @default.
• W2010641595 hasPublicationYear "2003" @default.
• W2010641595 type Work @default.
• W2010641595 sameAs 2010641595 @default.
• W2010641595 citedByCount "42" @default.
• W2010641595 countsByYear W20106415952012 @default.
• W2010641595 countsByYear W20106415952013 @default.
• W2010641595 countsByYear W20106415952015 @default.
• W2010641595 countsByYear W20106415952017 @default.
• W2010641595 countsByYear W20106415952018 @default.
• W2010641595 countsByYear W20106415952020 @default.
• W2010641595 crossrefType "journal-article" @default.
• W2010641595 hasAuthorship W2010641595A5042843111 @default.
• W2010641595 hasBestOaLocation W20106415951 @default.
• W2010641595 hasConcept C126322002 @default.
• W2010641595 hasConcept C164705383 @default.
• W2010641595 hasConcept C170493617 @default.
• W2010641595 hasConcept C2778468042 @default.
• W2010641595 hasConcept C2778525890 @default.
• W2010641595 hasConcept C71924100 @default.
• W2010641595 hasConceptScore W2010641595C126322002 @default.
• W2010641595 hasConceptScore W2010641595C164705383 @default.
• W2010641595 hasConceptScore W2010641595C170493617 @default.
• W2010641595 hasConceptScore W2010641595C2778468042 @default.
• W2010641595 hasConceptScore W2010641595C2778525890 @default.
• W2010641595 hasConceptScore W2010641595C71924100 @default.
• W2010641595 hasIssue "15" @default.
• W2010641595 hasLocation W20106415951 @default.
• W2010641595 hasLocation W20106415952 @default.
• W2010641595 hasOpenAccess W2010641595 @default.
• W2010641595 hasPrimaryLocation W20106415951 @default.
• W2010641595 hasRelatedWork W1967336868 @default.
• W2010641595 hasRelatedWork W1983068955 @default.
• W2010641595 hasRelatedWork W2005378862 @default.
• W2010641595 hasRelatedWork W2017346924 @default.
• W2010641595 hasRelatedWork W2044827976 @default.
• W2010641595 hasRelatedWork W2089173316 @default.
• W2010641595 hasRelatedWork W2089758216 @default.
• W2010641595 hasRelatedWork W2096740894 @default.
• W2010641595 hasRelatedWork W4234160658 @default.
• W2010641595 hasRelatedWork W2101116529 @default.
• W2010641595 hasVolume "108" @default.
• W2010641595 isParatext "false" @default.
• W2010641595 isRetracted "false" @default.
• W2010641595 magId "2010641595" @default.
• W2010641595 workType "article" @default.